Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RINDBeRG trial of ramucirumab plus irinotecan beyond ramucirumab progression in advanced gastric cancer
jRCTs051180187Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing Irinotecan alone with Ramucirumab plus irinotecan (2 arms). Primary endpoint: Overall survival. Started Feb 2017; status: completed.
02
Drugs
ramucirumabirinotecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs051180187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180187.